EFPIA welcomes EU step towards Innovate Medicines Initiative launch

16 April 2014

The European Parliament’s Industry, Research and Energy (ITRE) Committee voted in favor of the second Innovate Medicines Initiative (IMI2) yesterday.

The move has been welcomed by the European Federation of Pharmaceutical Industries and Associations (EFPIA) as another step towards the launch of the initiative which will continue the success of the first IMI, a public-private partnership between the European Union (EU) and EFPIA that aims to advance research and development, particularly in areas of unmet medical need.

IMI2 relied heavily on the World Health Organization’s Report on Priority Medicines for Europe and the World in determining its Strategic Research Agenda. IMI2 aims to deliver a 30% better success rate in clinical trials of priority medicines identified by the WHO; clinical proof of concept in immunological, respiratory, neurological and neurodegenerative diseases in just five years; and new and approved diagnostic markers for four of these diseases and at least two new medicines which could either be new antibiotics or new therapies for Alzheimer’s disease. The SRA, an essential element of the evolution from IMI to IMI2, was determined with input from more than 80 organizations, including regulators, patients and academia. The first five big questions to be addressed by IMI2 include neuro-degeneration, metabolic disorders, immune-mediated diseases, infections and translational safety.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Pharmaceutical